These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 18062731

  • 1. Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007.
    Kunze AM, Gunderson BW, Gleason PP, Heaton AH, Johnson SV.
    J Manag Care Pharm; 2007; 13(9):799-806. PubMed ID: 18062731
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacy benefit spending on oral chemotherapy drugs.
    Curtiss FR.
    J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
    [Abstract] [Full Text] [Related]

  • 5. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS.
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC, Marcoux RM, Quilliam BJ.
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C, Aloi JJ.
    Clin Ther; 2015 Apr 01; 37(4):691-715. PubMed ID: 25846320
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dalfampridine prior authorization program: a cohort study.
    Gleason PP, Phillips J, Fenrick BA, Delgado-Riley A, Starner CI.
    J Manag Care Pharm; 2013 Apr 01; 19(1):18-25. PubMed ID: 23383704
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
    Starner CI, Schafer JA, Heaton AH, Gleason PP.
    J Manag Care Pharm; 2008 Apr 01; 14(6):523-31. PubMed ID: 18693776
    [Abstract] [Full Text] [Related]

  • 19. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Tungol A, Starner CI, Gunderson BW, Schafer JA, Qiu Y, Gleason PP.
    J Manag Care Pharm; 2012 Apr 01; 18(9):690-700. PubMed ID: 23206212
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA, Kamal KM, Pawar G.
    J Manag Care Spec Pharm; 2017 Jun 01; 23(6):666-676. PubMed ID: 28530523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.